<SEC-DOCUMENT>0001104659-24-071330.txt : 20240613
<SEC-HEADER>0001104659-24-071330.hdr.sgml : 20240613
<ACCEPTANCE-DATETIME>20240613165803
ACCESSION NUMBER:		0001104659-24-071330
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240613
DATE AS OF CHANGE:		20240613

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		241041989

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2417251d1_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section&nbsp;14(a)
of the </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant &thinsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;
</FONT><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;
</FONT><FONT STYLE="font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Definitive Proxy Statement</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;
</FONT><FONT STYLE="font-size: 10pt">Definitive Additional Materials</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting Material Pursuant to
 &sect;240.14a-12</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 100%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Precipio, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Name of Registrant as Specified In Its Charter) </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">x</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
fee required.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Fee paid previously with preliminary materials.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Fee computed on table in exhibit required by Item&nbsp;25(b)
per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 77px; width: 404px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&thinsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4 Science Park </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New Haven, Connecticut 06511</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Precipio is requesting
Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The cost of a rescheduled shareholder meeting
could reach $100,000</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NEW HAVEN, CT, (June
12<SUP>th</SUP>, 2024)</B>&nbsp;&ndash; Management of specialty cancer diagnostics company <U><FONT STYLE="color: #165B8E">Precipio,
Inc.</FONT><FONT STYLE="color: #5A5A5A">&nbsp;</FONT><FONT STYLE="color: #165B8E">(NASDAQ: PRPO</FONT></U><FONT STYLE="color: #165B8E">)
</FONT>is requesting that <B><U>shareholders instruct their brokers</U></B> to vote their shares immediately today no later than 11pm
Eastern Time. In order to ensure that there is a quorum required for the shareholders&rsquo; meeting that is scheduled to take place
tomorrow June 13, 2024 at 10 a.m. Eastern Time.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At the time of this press
release, approximately 44% of shares have been voted. In order for the company to hold the shareholder meeting, a minimum of 50% of shares
must be voted.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If the company is forced
to adjourn the shareholder meeting due to insufficient votes, the costs of rescheduling the meeting, which includes hiring a proxy solicitor,
legal and other administrative costs could be as high as $100,000 (the current shareholder meeting costs less than $5,000).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>Management would like
to avoid these unnecessary expenditures</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Regardless of whether
you instruct your broker to vote for or against, PLEASE VOTE TODAY BY 11 p.m. Eastern Time to ensure that the quorum requirement is met,
and the&nbsp; costs of a rescheduled meeting are avoided.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Precipio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1pt; background-color: white">Precipio
is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses
by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved
laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies
in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes
these technologies as proprietary products that serve the global laboratory community and further scales Precipio&rsquo;s reach to eradicate
misdiagnosis. For more information, please visit <FONT STYLE="color: #1155CC"><U>www.precipiodx.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please follow us on <FONT STYLE="color: Blue"><U>LinkedIn</U></FONT>,
Twitter <FONT STYLE="color: Blue"><U>@PrecipioDx</U></FONT> and on <FONT STYLE="color: Blue"><U>Facebook</U></FONT>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, including, among others, including other financial projections and potential market opportunity, plans and prospects.
Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per
share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements
based on management&rsquo;s estimates, beliefs, assumptions and projections. Words such as &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;expects,&rdquo;
 &ldquo;anticipates,&rdquo; &ldquo;will,&rdquo; &ldquo;targets,&rdquo; &ldquo;goals,&rdquo; &ldquo;projects,&rdquo; &ldquo;intends,&rdquo;
 &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; and variations on such
words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance,
are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and
uncertainties, and actual results could differ materially from those discussed. We caution investors not to place undue reliance on the
forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov,
for a discussion of these and other risks and uncertainties Important factors that could affect performance and cause results to differ
materially from management&rsquo;s expectations, or could affect the company&rsquo;s ability to achieve its strategic goals, includes
factors that are described in the sections entitled &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis&rdquo;
in the company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated from time to time in the company&rsquo;s
Securities and Exchange Commission filings. The company&rsquo;s forward-looking statements in this press release are based on management&rsquo;s
current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company
undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise, except as required by the federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1155CC"><B><U>investors@precipiodx.com</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1155CC">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">+1-203-787-7888
Ext. 523</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;<B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !@ ?D# 2(  A$! Q$!_\0
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MY1<79FL9J2N@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6WOB+Q;J?C#4M,T2X0"V=@L>U!A5(&<MU/-3^3\3/^>D?_?4-'A/_DK6N_\
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MK7?^VO\ Z&M=7J?CC0M(OGL[N\Q.GWU1&;;[$@4ZB;:MV!'045RG_"R_#?\
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M=1@$\'F3/L)(Y##!X/O7KM>9>&O^2P:O_P!MOYK5TW9,3.I_X5[X8_Z!4?\
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MQV,73?"&AZ1>+=6&GQQ3J"%?<S$9ZXR3BMJBBDVWN 5P7Q=M6F\-VTX'$-P
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M2<F]V 52UC_D"7__ %[R?^@FKM4M8_Y E_\ ]>\G_H)H6X'#?!W_ )!6H_\
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MM,L3(">V1BF@. ^#O_(*U'_KLG_H->C5R7P^\,7GAG3+J/4&C\V:7<%C;(
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
